BNR Stock Analysis: Brenntag SE | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 8.568m EUR | 12M Return: 20.2% | DE000A1DAHH0 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.0M
EPS Trend: -82.9%
Qual. Beats: 0
Rev. Trend: -92.2%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Brenntag SE (XETRA: BNR) is a Germany-based global distributor of chemicals and ingredients, headquartered in Essen and founded in 1874. The company operates through two main segments: Brenntag Essentials, which focuses on broad-line industrial chemical distribution, and Brenntag Specialties, which targets higher-value, application-specific ingredients and solutions. Its geographic footprint spans Germany, the United States, the United Kingdom, China, Canada, Italy, Poland, France, and additional international markets.
The company provides a wide range of value-added services beyond pure distribution, including just-in-time delivery, product mixing, blending, repackaging, inventory management, drum return handling, application and formulation support, regulatory expertise, and digital solutions such as online sales channels and product platforms. This service-oriented model allows Brenntag to capture additional margin beyond simple product resale and to build deeper customer relationships.
Brenntag serves a diverse customer base across end markets such as nutrition, pharmaceuticals, beauty and personal care, water treatment, coatings, adhesives, sealants and elastomers (CASE), construction, polymers, and rubber. This breadth across both consumer-driven and industrial end markets helps diversify demand cycles, though exposure to cyclical industrial sectors means results can still be sensitive to broader manufacturing trends.
- Specialties segment margin expansion drives group operating profit growth
- Essentials volumes pressured by weak European industrial and coatings demand
- Acquisition pipeline and disciplined capital allocation support cash flow outlook
| Net Income: 364.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.04 > 1.0 |
| NWC/Revenue: 14.54% < 20% (prev 9.86%; Δ 4.68% < -1%) |
| CFO/TA 0.07 > 3% & CFO 802.8m > Net Income 364.3m |
| Net Debt (3.69b) to EBITDA (1.26b): 2.92 < 3 |
| Current Ratio: 1.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (144.0m) vs 12m ago -0.28% < -2% |
| Gross Margin: 15.69% > 18% (prev 25.04%; Δ -9.36% > 0.5%) |
| Asset Turnover: 134.9% > 50% (prev 148.3%; Δ -13.33% > 0%) |
| Interest Coverage Ratio: 4.84 > 6 (EBIT TTM 763.0m / Interest Expense TTM 157.7m) |
| A: 0.19 (Total Current Assets 5.34b - Total Current Liabilities 3.14b) / Total Assets 11.7b |
| B: 0.31 (Retained Earnings 3.65b / Total Assets 11.7b) |
| C: 0.07 (EBIT TTM 763.0m / Avg Total Assets 11.2b) |
| D: 0.62 (Book Value of Equity 4.43b / Total Liabilities 7.20b) |
| Altman-Z'' = 3.36 = A |
| DSRI: 1.31 (Receivables 3.16b/2.54b, Revenue 15.2b/16.0b) |
| GMI: 1.60 (GM 25.04% / 15.69%) |
| AQI: 0.96 (AQ_t 0.35 / AQ_t-1 0.37) |
| SGI: 0.95 (Revenue 15.2b / 16.0b) |
| TATA: -0.04 (NI 364.3m - CFO 802.8m) / TA 11.7b) |
| Beneish M = -2.29 (Cap -4..+1) = BBB |
As of October 07, 2026, the stock is trading at EUR 60.86 with a total of 252,126 shares traded. Over the past week, the price has changed by +2.67%, over one month by -0.10%, over three months by +8.52% and over the past year by +20.21%.
Current recommended Stop Loss: 58.90 (which is 3.2% or 1.5 ATR below the current price).
Brenntag SE has no consensus analysts rating.
P/E Trailing = 23.5476
P/E Forward = 10.8578
P/S = 0.5653
P/B = 1.9271
P/EG = 1.138
Revenue TTM = 15.2b EUR
EBIT TTM = 763.0m EUR
EBITDA TTM = 1.26b EUR
Long Term Debt = 2.60b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 337.0m EUR (from shortTermDebt, last quarter)
Debt = 4.20b EUR (from shortLongTermDebtTotal, last quarter) + Leases 588.0m
Net Debt = 3.69b EUR (calculated: Debt 4.20b - CCE 509.0m)
Enterprise Value = 12.3b EUR (8.57b + Debt 4.20b - CCE 509.0m)
Interest Coverage Ratio = 4.84 (Ebit TTM 763.0m / Interest Expense TTM 157.7m)
EV/FCF = 23.89x (Enterprise Value 12.3b / FCF TTM 513.1m)
FCF Yield = 4.19% (FCF TTM 513.1m / Enterprise Value 12.3b)
FCF Margin = 3.39% (FCF TTM 513.1m / Revenue TTM 15.2b)
Net Margin = 2.40% (Net Income TTM 364.3m / Revenue TTM 15.2b)
Gross Margin = 15.69% ((Revenue TTM 15.2b - Cost of Revenue TTM 12.8b) / Revenue TTM)
Gross Margin QoQ = 14.38% (prev 12.89%)
Tobins Q-Ratio = 1.05 (Enterprise Value 12.3b / Total Assets 11.7b)
Interest Expense / Debt = 3.76% (Interest Expense 157.7m / Debt 4.20b)
Taxrate = 39.95% (247.3m / 619.1m)
NOPAT = 458.2m (EBIT 763.0m * (1 - 39.95%))
Current Ratio = 1.70 (Total Current Assets 5.34b / Total Current Liabilities 3.14b)
Debt / Equity = 0.95 (Debt 4.20b / totalStockholderEquity, last quarter 4.43b)
Debt / EBITDA = 2.92 (Net Debt 3.69b / EBITDA 1.26b)
Debt / FCF = 7.19 (Net Debt 3.69b / FCF TTM 513.1m)
Total Stockholder Equity = 4.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.24% (Net Income 364.3m / Total Assets 11.7b)
RoE = 8.30% (Net Income TTM 364.3m / Total Stockholder Equity 4.39b)
RoCE = 10.92% (EBIT 763.0m / Capital Employed (Equity 4.39b + L.T.Debt 2.60b))
RoIC = 5.48% (NOPAT 458.2m / Invested Capital 8.36b)
WACC = 5.11% (E(8.57b)/V(12.8b) * Re(6.51%) + D(4.20b)/V(12.8b) * Rd(3.76%) * (1-Tc(0.40)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -4.61 | Cagr: -0.12%
[DCF] Terminal Value 73.55% ; FCFF base≈542.3m ; Y1≈487.4m ; Y5≈413.6m
[DCF] Fair Price = 20.16 (EV 6.60b - Net Debt 3.69b = Equity 2.91b / Shares 144.4m; r=8.35% [WACC [floored]]; 5y FCF grow -12.46% → 2.50% )
EPS Correlation: -82.93 | EPS CAGR: -26.37% | SUE: -0.10 | # QB: 0
Revenue Correlation: -92.22 | Revenue CAGR: -4.81% | SUE: 1.46 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.18 | Chg30d=+13.32% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=4.14 | Chg30d=-0.01% | Revisions=+55% | GrowthEPS=+84.7% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=4.18 | Chg30d=+0.26% | Revisions=+0% | GrowthEPS=+0.9% | GrowthRev=-0.3%
[Analyst] Revisions Ratio: +29% (up=12, down=6)